Company profile for Treos Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by o...
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
The Harley Building, 79 New Cavendish Street, London W1W 6XB
Telephone
Telephone
+44-20-3141 7370
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/08/27/3139866/0/en/TREOS-Bio-Partners-with-Charit%C3%A9-Berlin-and-Junshi-Biosciences-to-Launch-Pivotal-Phase-II-Clinical-Trial-in-Refractory-MSS-Colorectal-Cancer.html

GLOBENEWSWIRE
27 Aug 2025

https://www.globenewswire.com/news-release/2024/09/09/2943229/0/en/New-Meta-Analysis-Shows-Treos-Bio-s-Promiscuous-Epitopes-in-Their-Off-The-Shelf-Colorectal-Cancer-Immunotherapy-Produce-Stronger-Immune-Response-than-Traditional-Epitopes.html

GLOBENEWSWIRE
09 Sep 2024

https://www.globenewswire.com/news-release/2024/06/03/2892106/0/en/At-ASCO-2024-Treos-Bio-Reports-Key-Survival-Results-for-Chemo-Free-Regimen-of-PolyPEPI1018-Peptide-Immunotherapy-and-Roche-s-PD-L1-Inhibitor-in-Late-Stage-Colorectal-Cancer.html

GLOBENEWSWIRE
03 Jun 2024

https://www.globenewswire.com/news-release/2024/05/08/2877730/0/en/Treos-Bio-to-Present-New-Clinical-Data-on-Off-the-Shelf-Peptide-Immunotherapy-for-Colorectal-Cancer-at-2024-ASCO-Annual-Meeting.html

GLOBENEWSWIRE
08 May 2024

https://finance.yahoo.com/news/treos-bio-announces-14-million-110000740.html#:~:text=(%2D0.86%25)-,Treos%20Bio%20Announces%20%2414%20Million%20Convertible%20Loan%20Note%20Financing%20to,Designed%20Peptide%2DBased%20Cancer%20Immunotherapies&text=In%20an%20earlier%20Phase%20I,and%20durable%20anti%2Dtumor%20responses.

YAHOO
31 Mar 2021

https://www.globenewswire.com/news-release/2020/06/15/2047955/0/en/Treos-Bio-Forms-New-Subsidiary-to-Develop-a-Preventive-COVID-19-Peptide-Vaccine.html

GLOBENEWSWIRE
15 Jun 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty